CHF84.42
0.31% yesterday
SIX Swiss Exchange, Oct 02, 05:30 pm CET
ISIN
CH0432492467
Symbol
ALC

Alcon Stock price

CHF84.42
+2.28 2.78% 1M
+10.34 13.96% 6M
+18.78 28.61% YTD
+14.80 21.26% 1Y
+12.16 16.83% 3Y
+27.74 48.94% 5Y
+26.37 45.43% 10Y
SIX Swiss Exchange, Closing price Wed, Oct 02 2024
+0.26 0.31%
ISIN
CH0432492467
Symbol
ALC
Sector

Key metrics

Market capitalization CHF41.64b
Enterprise Value CHF44.99b
P/E (TTM) P/E ratio 42.62
EV/FCF (TTM) EV/FCF 41.61
EV/Sales (TTM) EV/Sales 5.26
P/S ratio (TTM) P/S ratio 4.87
P/B ratio (TTM) P/B ratio 2.22
Dividend yield 0.28%
Last dividend (FY23) CHF0.24
Revenue growth (TTM) Revenue growth 0.44%
Revenue (TTM) Revenue CHF8.55b
EBIT (operating result TTM) EBIT CHF1.27b
Free Cash Flow (TTM) Free Cash Flow CHF1.08b
Cash position CHF1.23b
EPS (TTM) EPS CHF1.98
P/E forward 51.18
P/S forward 4.92
EV/Sales forward 5.31
Show more

Create a Free Account to create an Alcon alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Alcon Stock Analysis

Analyst Opinions

29 Analysts have issued a Alcon forecast:

23x Buy
79%
4x Hold
14%
2x Sell
7%

Analyst Opinions

29 Analysts have issued a Alcon forecast:

Buy
79%
Hold
14%
Sell
7%

Financial data from Alcon

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
8,552 8,552
0% 0%
100%
- Direct Costs 3,817 3,817
4% 4%
45%
4,735 4,735
2% 2%
55%
- Selling and Administrative Expenses 1,637 1,637
16% 16%
19%
- Research and Development Expense 735 735
2% 2%
9%
2,364 2,364
9% 9%
28%
- Depreciation and Amortization 1,091 1,091
2% 2%
13%
EBIT (Operating Income) EBIT 1,273 1,273
15% 15%
15%
Net Profit 978 978
195% 195%
11%

In millions CHF.

Don't miss a Thing! We will send you all news about Alcon directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alcon Stock News

marktEINBLICKE
about one year ago
Alcon konnte überzeugende Ergebnisse vorlegen und seine Prognose anheben. In Sachen Bewertung bleiben allerdings einige Fragezeichen.
marktEINBLICKE
more than one year ago
Novartis musste 2022 mit dem starken US-Dollar fertig werden. Dafür überzeugte das Pharmaunternehmen mit einigen neuen Medikamenten.

Company Profile

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.

Head office Switzerland
CEO David Endicott
Employees 25,315
Founded 1945
Website www.alcon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today